Vesting of awards under the LTIP

RNS Number : 9839R

Hutchmed (China) Limited

06 March 2023

 

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ - Monday, March 6, 2023: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2022 annual results of HUTCHMED on February 28, 2023, the following awards granted under the Long Term Incentive Plan ("LTIP") on April 20, 2020 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 3, 2023:-

Award Holders	Number of American depositary shares ("ADS")
Person Discharging Managerial Responsibilities
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer)	50,431
Mr Johnny Cheng (Executive Director and Chief Financial Officer)	22,953
Total	73,384

The notification s set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

(a)  Dr Weiguo Su

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Dr Weiguo Su
2	Reason for the notification
a)	Position/status	Executive Director, Chief Executive Officer and Chief Scientific Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	HUTCHMED (China) Limited
b)	LEI	2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	ADS each representing five Ordinary Shares of US$0.10 ADS ISIN: US44842L1035
b)	Nature of the transaction	Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil 50,431 ADS
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	2023-03-03
f)	Place of the transaction	Outside a trading venue

(b)  Mr Johnny Cheng

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Mr Johnny Cheng
2	Reason for the notification
a)	Position/status	Executive Director and Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	HUTCHMED (China) Limited
b)	LEI	2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	ADS each representing five Ordinary Shares of US$0.10 ADS ISIN: US44842L1035
b)	Nature of the transaction	Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
c)	Price(s) and volume(s)	Price(s) Volume(s) Nil 22,953 ADS
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	2023-03-03
f)	Place of the transaction	Outside a trading venue

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has about 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception HUTCHMED has been focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

CONTACTS

Investor Enquiries
Mark Lee, Senior Vice President	[phone]
Annie Cheng, Vice President	[phone]
Media Enquiries
Americas - Brad Miles, Solebury Trout	[phone]   (Mobile) [e-mail]
Europe - Ben Atwell / Alex Shaw, FTI Consulting	[phone] / [phone]   (Mobile) / [phone] (Mobile)  [e-mail]
Asia - Zhou Yi, Brunswick	[phone]   (Mobile) [e-mail]
Nominated Advisor
Atholl Tweedie / Freddy Crossley, Panmure Gordon (UK) Limited	[phone]

 

END

 

 

DSHJFMRTMTIMMBJ